Lymphomas

Expert faculty review and share their insights and perspectives on key findings in lymphomas presented at the 2022 ASH Annual Meeting.

Share

Program Content

Activities

  • ASH 2022: Lymphomas and CLL
    Key Studies in Lymphomas and CLL: Independent Conference Coverage of ASH 2022
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 17, 2023

    Expires: April 16, 2024

Activities

TRIANGLE
TRIANGLE: Phase III Trial of Ibrutinib + CIT With or Without ASCT vs CIT Followed by ASCT in Younger Patients With Previously Untreated MCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

AN + AD for cHL
Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine as Frontline Combination Therapy for Advanced-Stage cHL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

PhaseED-Seq MRD in DLBCL
Pooled Analysis of PhaseED-Seq MRD-Negativity Assessment as Surrogate Endpoint After Frontline Induction Therapy in Patients With DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

AVO in High-Risk CLL
Phase II Trial: Updated Results of Frontline Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Untreated High-Risk CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

Phase I/II EPCORE NHL-2
Phase I/II EPCORE NHL-2 Trial Update: Epcoritamab + Rituximab/Lenalidomide in Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

Acalabrutinib/LenR in MCL
Acalabrutinib + Lenalidomide and Rituximab With MRD Monitoring in Previously Untreated Mantle Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

BV + AVD in Unfavorable-Risk cHL
Extended Follow-up Results From a Pilot Study of Brentuximab Vedotin + AVD in Newly Diagnosed, Early-Stage, Unfavorable-Risk cHL Using Baseline MTV and PET2 Evaluation
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

CAPTIVATE MRD Cohort
CAPTIVATE: 5-Yr Follow-up of Continued Ibrutinib vs Placebo in Patients With CLL/SLL and Undetectable MRD After First-line Ibrutinib + Venetoclax
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2022

Expires: December 13, 2023

SYMPHONY-1: Phase Ib Results
SYMPHONY-1: Phase Ib Results of Tazemetostat + Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

MATRix/IELSG43
MATRix/IELSG43: Phase III Trial of High-Dose Chemotherapy + ASCT vs Nonmyeloablative Chemoimmunotherapy as Consolidation for Primary CNS Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

ALPINE: Final Analysis
ALPINE: Final Analysis of Zanubrutinib vs Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen